Alexion's long-acting C5 inhibitor meets in Phase III switch trial

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported in its 1Q18 earnings release on April 26 that ALXN1210, its long-acting formulation of Soliris eculizumab, met the primary and four key secondary endpoints in the the Phase III ALXN1210-PNH-302 trial to treat

Read the full 386 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE